tiprankstipranks
Sage Therapeutics cut to Underperform at BofA after Parkinson’s trial fails
PremiumThe FlySage Therapeutics cut to Underperform at BofA after Parkinson’s trial fails
2d ago
Sage Therapeutics downgraded to Underperform from Neutral at BofA
PremiumThe Fly
Sage Therapeutics downgraded to Underperform from Neutral at BofA
2d ago
Sage Therapeutics down 19% at $12.60 after announcing dalzanemdor Phase 2 data
PremiumThe Fly
Sage Therapeutics down 19% at $12.60 after announcing dalzanemdor Phase 2 data
2d ago
Sage Therapeutics management to meet with Piper Sandler
PremiumThe FlySage Therapeutics management to meet with Piper Sandler
24d ago
Sage Therapeutics price target raised to $29 from $24 at JPMorgan
PremiumThe Fly
Sage Therapeutics price target raised to $29 from $24 at JPMorgan
24d ago
JPMorgan biotech analysts to hold an analyst/industry conference call
PremiumThe Fly
JPMorgan biotech analysts to hold an analyst/industry conference call
2M ago
Sage Therapeutics price target raised to $25 from $23 at Oppenheimer
PremiumThe FlySage Therapeutics price target raised to $25 from $23 at Oppenheimer
2M ago
Bad News for SAGE Therapeutics, Inc. (US) Stock: This New Risk Has Been Added
PremiumMarket News
Bad News for SAGE Therapeutics, Inc. (US) Stock: This New Risk Has Been Added
2M ago
Sage Therapeutics price target raised to $28 from $27 at Goldman Sachs
PremiumThe Fly
Sage Therapeutics price target raised to $28 from $27 at Goldman Sachs
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100